GUTS

Fractyl is a pre-revenue, clinical-stage metabolic-therapeutics company, and the financials read exactly like one: FY2025 revenue was $0.00 (down from an already trivial $93K in FY2024), net loss ballooned to -$141M, operating cash flow was -$90.3M, and the accumulated deficit sits at -$556M. This is not a business yet — it is a research program (R&D $74.5M) funded by shareholders. Stockholders' equity has collapsed to $9.46M against $112M of liabilities (11.84x), and the -1,490% ROE is a mechanical artifact of a razor-thin equity base being consumed by losses. Share count exploded +224% to 159M, confirming the funding model is serial, heavily dilutive equity issuance.

The MD&A is candid that this is a race against the cash clock: management says the $81.5M cash balance plus $4.1M of January 2026 Tranche A warrant proceeds funds operations only 'into early 2027.' The company itself flags a going-concern assessment. That runway does not comfortably clear the events that matter — REMAIN-1 Pivotal topline six-month data is only expected in 'early fourth quarter of 2026' and a potential FDA De Novo submission in 'late fourth quarter of 2026.' In practice the company will almost certainly need to raise again — likely before the market has fully digested the pivotal readout — which means dilution risk is stacked on top of clinical risk.